COVID-19 – GLOBAL CHALLENGE OF OUR TIME

Eli Dimitrovska; Marija Avramoska

doi:10.35120/medisij010307d

Authors

Eli Dimitrovska Clinical Hospital Bitola, Republic of North Macedonia
Marija Avramoska Bosnalijek JSC R.O. in R.N. Macedonia-Skopje, Republic of North Macedonia

DOI:

https://doi.org/10.35120/medisij010307d

Keywords:

Covid-19, SARS-CoV-2, pneumonia, post Covid conditions

Abstract

Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. The first diagnosed case of COVID 19 in Macedonia with a PCR diagnostic test was on February 27, 2020. The first diagnosed case of COVID 19 in Bitola with a PCR diagnostic test was on April 03, 2020.
The purpose of this paper is to present our experiences in the fight against the new unknown disease, with special reference to clinical expressions and post-covid conditions. A great problem and challenge for the infectologists in Clinical Hospital, Bitola, were the therapeutic possibilities, especially in treatment of patients with multiple comorbid conditions. This paper covers patients who were treated in the Infectious Diseases department’s COVID-19 center at the Clinical Hospital, over a period of 2 years.The fight against the SARS-CoV 2 continues and we are already facing the new - seventh wave of the pandemic.

Downloads

Download data is not yet available.

References

Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H.Y., Luetkemeyer, A., Kline, S., De Castilla D.L., Finberg, R.W.,(2020) Remdesivir for the Treatment of Covid-19 — Final Report. The New England Journal of Medicine 383:1813-1826

Chen, P.J., Chao, C., Lai, C.C. (2021). Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients. Journal of infection

Chowdhury, J.F., Moores, L.K., Connors J.M., (2020).Anticoagulation in hospitalized patients with Covid-19. The New England Journal of Medicine. 383:1675-1678.

Gottlieb, R.L., Vaca, C.E., Paredes, R., Mera, J., Webb, B.J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B.U., Brown, M., Hidalgo, A., Sachdeva, J. (2021). Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. The New England Journal of Medicine 386:305-315

Eroglu, E., Toprak, C. (2021). Overview of favipiravir and remdesivir treatment for COVID-19. International Journal of Pharmaceutical Sciences and Researcgh, Volume 12 (4) 1950-1957

Gupte, V., Hegde, R., Sawant, S., Kalathingal, K., Jadhav, S., Malabade, R., Gogtay, J. (2022). Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infectious Diseases 22:1

Ionescu, F., Jaiyesimi, I., Petrescu, I., et al. (2021). Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. European Journal of Haematology 06:165-174.

Joshi, Sh., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., Barkate, H. (2021). Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases, Volume 102, 501-508

Manabe, T., Kambayashi, D., Akatsu, H., Kudo, K., (2021). Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infectious Diseases 21:489

Mariette, X., Hermine, O., Tharaux, P.L. (2021) Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19 A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. JAMA Internal Medicine 181(9):1241-1243

Özlüşen, B., Kozan, S., Akcan, R.E., Mekselina, K., Yaprak, D., Peltek, I.B., Keske, S., Gönen, M., Ergönül, O., (2021). Efectiveness of favipiravir in COVID‑19: a live systematic review. European Journal of Clinical Microbiology & Infectious Diseases 40:2575–2583

Rezagholizadeh, A., Khiali, S., Sarbakhsh, P., Entezari-Malekia, T. (2021). Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. European journal of pharmacology 897: 173926

Rosas, I.O.,M.D., Bräu, N., Waters, M., Go, R.C., Hunter, B.D., Bhagani, S., Skiest, D., Aziz, M.S., Cooper, N., Douglas, I.S., Savic, S., Youngstein, T. (2021). Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England Journal of Medicine 384:1503-1516

Sadeghipour, P., Talasaz, A.H., Rashidi, F., et al. (2021). Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the inspiration randomized clinical trial. JAMA Internal Medicine 325:1620-1630.

Wei, Q., Lin, H., Wei, R.G., Chen, N., He, F., Zou, D.H., Wei, J.R., (2021). Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infectious Diseases of Poverty 10:71